We report a case of lethal neonatal hypoxic respiratory failure and hypothyroidism in an infant with a novel missense mutation in
Introduction NKX2.1 encodes thyroid transcription factor-1, a nuclear protein expressed in the brain, lung and thyroid during embryonic development. 1 Heterozygous mutations and deletions in NKX2.1 are associated with Brain-Lung-Thyroid Syndrome (BLTS, OMIM no. 610978), whose features include congenital hypothyroidism, pulmonary dysfunction and neurological impairment with variable phenotypic severity. [2] [3] [4] [5] We report a novel missense mutation in NKX2.1 identified in an infant with respiratory failure and hypothyroidism in the immediate postnatal period.
Methods
Immunohistochemistry was performed on sequential, formalinfixed, paraffin-embedded, 5-mm lung sections on a Ventana automated immunostainer (Ventana Medical Systems, Tucson, AZ, USA) after antigen retrieval, using the following antibodies: thyroid transcription factor-1 (1:50) and thyroglobulin (1:100; both mouse monoclonal; Thermo Scientific, Rockford, IL, USA), surfactant proteins (SP)-A (1:4000), SP-B (1:2000) and proSP-C (1:2000; all rabbit polyclonal; Chemicon, Temecula, CA, USA), CC10/CCSP (1:1000, rabbit polyclonal; Santa Cruz Biotechnology Inc, Santa Cruz, CA), ABCA3 (1:1000, rabbit polyclonal; Seven Hills Bioreagents, Cincinnati, OH, USA).
Case
A female infant was born by spontaneous vaginal delivery at 39 weeks and 5 days gestation to a 22-year-old Gravida 2 Para 1 female. The pregnancy was complicated by a positive Group B streptococcus culture treated before delivery. At birth, meconium-stained amniotic fluid, poor respiratory effort and cyanosis were noted. Apgar scores were 5, 6 and 7 at 1, 5 and 10 min, respectively. The infant weighed 2839 g (9th percentile). A two-vessel cord was noted on physical examination. A chest radiograph demonstrated bilateral hazy lung fields consistent with respiratory distress syndrome. Despite surfactant administration, respiratory status continued to worsen and bilateral pneumothoraces occurred, necessitating support escalation to high-frequency oscillatory ventilation and inhaled nitric oxide. Hypotension developed requiring pressor support with inotropic drips, and echocardiogram revealed severe right ventricular dysfunction. Given persistent hypoxemic respiratory failure, the infant was transferred to our tertiary care facility on day of age 1 and placed on venoarterial extracorporeal membrane oxygenation (ECMO). Following placement on ECMO, inotropic support was no longer required.
Newborn screening revealed an elevated thyroid-stimulating hormone of 180.7 mIU ml À1 and levothyroxine replacement was started. Hypothyroidism was confirmed at 1 week of life with a thyroid-stimulating hormone of 93.7 mIU ml À1 and low, normal, free thyroxine (1.1 ng dl À1 ). Initial blood cultures remained without growth. Throughout hospitalization, the infant exhibited unremitting respiratory failure in the setting of significant pulmonary hypertension with the right heart failure by echocardiography. Following multiple unsuccessful attempts to support the infant off ECMO, the decision was made to withdraw care on day of age 28.
The combination of neonatal respiratory failure and hypothyroidism led to clinical suspicion of BLTS and sequencing of NKX2.1. Sequencing by Nemours Molecular Diagnostics Laboratory (Wilmington, DE, USA) revealed a novel heterozygous missense mutation in exon 3 of NKX2.1, c.621C > G with resultant amino acid substitution p.Ile207Met. No mutations were detected in SFTPB or SFTPC, which encode SP, or ABCA3, which is critical for surfactant metabolism. 6 Although the infant's parents elected not to undergo genetic testing themselves, family histories of respiratory impairment and thyroid disease were denied.
At autopsy, the lungs were severely congested (combined lung weight 121.7 g, expected 60 g) with diffuse alteration of the architecture by alveolar remodeling and Type II cell hyperplasia. There was alveolar filling by granular proteinaceous material, focally periodic acid-Schiff-positive, diastase resistant, as well as macrophages, edema and fibrin (Figure 1b) . The radial alveolar count was markedly reduced (average 2, expected >5) 7 ( Figure 1a) . Immunohistochemical staining for SP was remarkable for near-complete absence of proSP-C within type II pneumocytes (Figure 1c ), but intact SP-B, SP-A, ABCA3 and Clara cell secretory protein. Compared with age-matched controls, there was no detectable difference in the pattern or intensity of NKX2.1 staining (Figure 1d) . By ultrastructural analysis, numerous well-formed lamellar bodies were present within type II pneumocytes, which comprised the majority (>75%) of the alveolar epithelial cells. The heart (23.1 g, expected 20 g) had a patent ductus arteriosus with no ischemic or hypertrophic change. 8 The thyroid gland was symmetrical and appeared appropriate size for age. Microscopic examination showed colloid depletion, but normally formed follicles and follicular epithelium ( Figure 2a) ; expression levels of NKX2.1 (Figure 2b ) and thyroglobulin were comparable to controls. The brain weight was reduced Novel NKX2.1 mutation in neonate ES Gillett et al (349 g, expected 413 g) with gross and microscopic appearance indistinguishable from the changes seen with hypoxic ischemic encephalopathy. 8 
Discussion
We report a second case of lethal neonatal respiratory distress at birth in an infant with BLTS. 9 We also discovered a novel heterogyzous mutation in NKX2.1 predicted to encode an p.Ile207Met amino acid substitution as causative for this BLTS case. This mutation maps to the DNA-binding domain of NKX2.1. Although the parents refused genetic testing, most BLTS cases result from spontaneous mutation. A different substitution of this same amino acid residue, p.Ile207Phe, has been reported previously by Maquet et al. 9 in an infant with a similar clinical course. Together, these observations suggest that disruption of this amino acid residue might be predictive of poor outcome due to severe pulmonary dysfunction. This hypothesis is supported by functional studies demonstrating that p.Ile207Phe substitution results in abnormal DNA binding and transactivation of the thyroglobulin and SP-B genes. 9 Described lung pathology in individuals with NKX2.1 mutations is limited and varied. [9] [10] [11] [12] Although the predominant histological feature is altered surfactant metabolism with pulmonary alveolar proteinosis, other cases have demonstrated deficient lung growth as the principal defect. 10 Pulmonary alveolar proteinosis, significant pulmonary hypoplasia and a striking reduction in proSP-C expression were all present in our case, as well as superimposed diffuse alveolar damage. Unlike the report by Maquet et al.,
9 SP-B expression was intact. Altered SP expression has been seen in some NKX2.1 mutations, 9 -11 and NKX2.1 has known regulatory effects on the SP-C gene expression. 13 Reports of thyroid pathology in individuals with NKX2.1 mutations are variable and range from normal architecture to hemiagenesis. 9 -11 Individuals with NKX2.1 mutations frequently have clinical and pathological neurological brain alterations, 14 but no changes beyond those associated with hypoxic ischemic encephalopathy were evident.
This case raised questions about the appropriateness and timing of lung biopsy in neonates showing minimal clinical improvement on ECMO. Although limited empirical data are available to guide biopsy timing, a retrospective analysis of 173 neonates with acute hypoxemic respiratory failure treated with ECMO recommended considering lung biopsy after 7 to 10 days in infants with symptoms of alveolar capillary dysplasia. 15 Open-lung biopsy is safe in patients on ECMO 16 and might have shortened ECMO duration in this case once lung pathology became apparent.
Earlier access to diagnostic genetic testing results might also have facilitated decision-making about the level and length of supportive care provided. Genetic testing results were not available until after the infant expired off ECMO. This clinical presentation was consistent with only a limited number of genetic diagnoses. The targeted sequencing of NKX2.1 and screening of other candidate genes to exclude alternative diagnoses represents a current state-of-the-art molecular diagnostic approach. A list of laboratories that test for NKX2.1 mutations is available at genetests.org. 17 In summary, we report the clinical characteristics of an infant who died from severe pulmonary insufficiency caused by a novel mutation in NKX2.1. This is the second reported case of a neonatal death from respiratory failure due to a heterozygous NKX2.1 mutation. Screening of NKX2.1 should be considered in all neonates who present with respiratory distress and hypothyroidism at birth.
